Skip to main content
. 2020 Feb 20;10:3017. doi: 10.1038/s41598-020-59929-w

Figure 4.

Figure 4

Time-course of the analgesic properties of LIT-001 on CFA-induced inflammatory pain model. (a) Scheme of the CFA-induced inflammatory pain model followed by i.p. LIT-001 injection. (b) Left, time-course of the effects of i.p. LIT-001 10 mg/kg (n = 8), its vehicule (n = 7) or co-injection with L-368,699 (n = 7), on CFA-induced edema size (CFA, n = 14; NaCl, n = 18). Right, relative-to-baseline AUC (%) of the effects. (c) Left, time-course of the effects of i.p. LIT-001 10 mg/kg (n = 7), its vehicule (n = 8) or co-injection with L-368,699 (n = 6) on CFA-induced mechanical (c1) and thermal heat (c2) hyperalgesia. Right, relative-to-baseline AUC (%) of the effects. (d) Left, time-course of the effects of i.p. LIT-001 10 mg/kg (n = 7), its vehicule (n = 8) or co-injection with L-368,699 (n = 6) on mechanical (d1) and thermal heat (d2) sensitivities of NaCl-injected hindpaw. Right, relative-to-baseline AUC (%) of the effects. Data are expressed as mean ± SEM. Asterisks indicate statistical significance (***p < 0.001; **p < 0.01; *p < 0.05) using two-way ANOVA followed by Tukey’s multiple comparisons test.